【CNS文章设计初稿】Cell文章设计2：把AIR自动限幅写成CAR-T信号调控文章

题目

AIR modules tune CAR-T signaling amplitude to preserve memory-like persistence

中文定位

摘要

本文围绕 AIR 结构域能否成为 CAR-T 内置刹车展开。方案以 Cell 2026 母论文为起点，将 CAR 信号、ADAM17 介导的受体剪切、AIR 自动抑制模块和实体瘤 CAR-T 持久性放在同一条机制链中。研究先通过 PubMed、UniProt、HPA、Reactome、STRING、ClinicalTrials 和 cBioPortal 核验证据，再用 CAR 结构工程、剪切片段检测、长期刺激模型、单细胞组学和体内验证建立因果闭环。

创新点

把抑制结构域写成可量化信号工程模块。
连接 NFAT/NF-kB/AP-1 输出与耗竭轨迹。
提出 CAR 设计中的内源性安全限幅框架。
明确区分探索性数据库证据与验证性干预实验，避免把相关性写成因果。
将 Cell 母文发现转化为可申报、可发表、可失败解释的研究路线。

生信分析方案

公开 CAR 结构域文献。
T 细胞耗竭单细胞参考图谱。
转录因子活性评分。
AIR 与检查点通路证据整合。
预注册主分析以 donor、CAR 构建或动物为统计单位；单细胞数据只用于状态分解和机制候选。
多重检验和亚组探索必须标注为探索性，不作为确认性结论。

湿实验方案

AIR-CAR 与传统 CAR 平行构建。
报告基因测信号幅度。
长期抗原刺激耗竭实验。
单细胞转录组/ATAC。
记忆样表型和体内扩增验证。
主终点包括表面 CAR 密度、sCAR 片段、杀伤曲线、细胞因子释放、耗竭比例、记忆样表型和体内肿瘤控制。
所有关键结论需要至少两个 CAR 构建或两个 donor 复核，并设置救援实验。

预期研究结论

预期证明 AIR 通过调控信号幅度降低耗竭并保留杀伤。若成立，AIR/ADAM17 轴将成为 CAR-T 合成免疫治疗中可调控的细胞自主反馈系统；若不成立，也能输出 CAR 结构稳定性、安全限幅或患者排除标准。

专家级点评

该方案的优势是紧贴 Cell 母文但不重复，能回答 CAR-T 工程设计中“为什么强信号不一定带来强疗效”的核心问题。主要风险是 ADAM17 作用可能具有上下文依赖性，因此必须通过抑制、敲低、救援和不同抗原密度模型证明机制边界。

参考文献

Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis. Cell. 2026. PMID: 42143019. https://pubmed.ncbi.nlm.nih.gov/42143019/
CAR-T therapy in solid tumors. Cancer cell. 2025. PMID: 40233718. https://pubmed.ncbi.nlm.nih.gov/40233718/
CAR immune cells: design principles, resistance and the next generation. Nature. 2023. PMID: 36813894. https://pubmed.ncbi.nlm.nih.gov/36813894/
Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023. PMID: 36890224. https://pubmed.ncbi.nlm.nih.gov/36890224/
NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019. PMID: 30814732. https://pubmed.ncbi.nlm.nih.gov/30814732/
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024. PMID: 38600376. https://pubmed.ncbi.nlm.nih.gov/38600376/
RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022. PMID: 36002574. https://pubmed.ncbi.nlm.nih.gov/36002574/
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer cell. 2022. PMID: 34971569. https://pubmed.ncbi.nlm.nih.gov/34971569/
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nature medicine. 2025. PMID: 39920391. https://pubmed.ncbi.nlm.nih.gov/39920391/
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1. Journal for immunotherapy of cancer. 2024. PMID: 38609317. https://pubmed.ncbi.nlm.nih.gov/38609317/
Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells. Cytotherapy. 2023. PMID: 36396552. https://pubmed.ncbi.nlm.nih.gov/36396552/
Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. Molecular therapy. Oncology. 2024. PMID: 38939825. https://pubmed.ncbi.nlm.nih.gov/38939825/
T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors. Cancer immunology research. 2023. PMID: 37070661. https://pubmed.ncbi.nlm.nih.gov/37070661/
Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1. Retrovirology. 2014. PMID: 24924541. https://pubmed.ncbi.nlm.nih.gov/24924541/
ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells. Scientific reports. 2019. PMID: 30940840. https://pubmed.ncbi.nlm.nih.gov/30940840/
B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138. Biochemical and biophysical research communications. 2020. PMID: 31771880. https://pubmed.ncbi.nlm.nih.gov/31771880/
LAG3's Enigmatic Mechanism of Action. Frontiers in immunology. 2020. PMID: 33488626. https://pubmed.ncbi.nlm.nih.gov/33488626/
T cell circuits that sense antigen density with an ultrasensitive threshold. Science (New York, N.Y.). 2021. PMID: 33632893. https://pubmed.ncbi.nlm.nih.gov/33632893/
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. PMID: 34380639. https://pubmed.ncbi.nlm.nih.gov/34380639/
Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cellular and molecular life sciences : CMLS. 2021. PMID: 34966954. https://pubmed.ncbi.nlm.nih.gov/34966954/
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood. 2022. PMID: 35507686. https://pubmed.ncbi.nlm.nih.gov/35507686/
CAR T Cells Engineered to Target Low-Density Antigens Show Efficacy and Safety. Cancer discovery. 2022. PMID: 35031552. https://pubmed.ncbi.nlm.nih.gov/35031552/
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta pharmaceutica Sinica. B. 2022. PMID: 35530130. https://pubmed.ncbi.nlm.nih.gov/35530130/
The role of A Disintegrin and Metalloproteinase (ADAM)-10 in T helper cell biology. Biochimica et biophysica acta. Molecular cell research. 2022. PMID: 34982961. https://pubmed.ncbi.nlm.nih.gov/34982961/